Protagonist Therapeutics, Inc.
PTGX
Rangering i aksjer
#2249
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
Aksjekurs
$138.50
Sist synkronisert: 2026-10-20
Markedsverdi
$8.96B
Endring (1 dag)
3.02%
Endring (1 år)
84.67%
Land
US
Handel Protagonist Therapeutics, Inc. (PTGX)
Kategori
Healthcare
Antall utestående aksjer for Protagonist Therapeutics, Inc. (PTGX)
Antall utestående aksjer per June 2026: 65.94M
Ifølge Protagonist Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 65.94M. Ved slutten av December 2023 hadde selskapet 56.76M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Protagonist Therapeutics, Inc. (PTGX) fra 2014 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 65.94M | 7.10% |
| 2024 | 61.57M | 8.46% |
| 2023 | 56.76M | 15.74% |
| 2022 | 49.04M | 5.87% |
| 2021 | 46.32M | 34.67% |
| 2020 | 34.40M | 32.84% |
| 2019 | 25.89M | 15.78% |
| 2018 | 22.36M | 26.39% |
| 2017 | 17.69M | 172.15% |
| 2016 | 6.50M | 10.48% |
| 2015 | 5.88M | 0.00% |
| 2014 | 5.88M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 285.07% |
US
|
|
| 396.00M | 500.58% |
US
|
|
| 478.91M | 626.33% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -5.69% |
NL
|
